STLN
The Oncology Institute, Inc.
6.20$
-3.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 83.5% | 85.4% | 86.1% | 84.0% | 84.2% | 83.2% | 84.3% | |
| 16.5% | 14.6% | 13.9% | 16.0% | 15.8% | 16.8% | 15.7% | |
| 24.3% | 22.5% | 18.5% | 19.8% | 19.1% | 18.6% | 19.0% | |
| 109.5% | 109.4% | 19.8% | 20.9% | 20.2% | 19.7% | 20.1% | |
| -9.5% | -9.4% | -5.9% | -4.9% | -4.4% | -2.9% | -4.4% | |
| 5.3% | 1.6% | 1.4% | 1.3% | 1.3% | 1.2% | 1.3% | |
| -18.8% | -14.3% | -12.1% | -5.3% | -1.7% | -6.1% | -6.2% | |
| -18.8% | -14.2% | -12.1% | -5.3% | -1.7% | -6.1% | -6.2% | |
| – | -11.2% | -9.4% | -2.8% | 0.7% | -3.8% | -3.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.